These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 29699924)

  • 41. Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
    Yang J; Chen W; Kang D; Lu X; Li X; Liu Z; Huang B; Daelemans D; Pannecouque C; De Clercq E; Zhan P; Liu X
    Eur J Med Chem; 2016 Feb; 109():294-304. PubMed ID: 26802545
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
    Kang D; Fang Z; Li Z; Huang B; Zhang H; Lu X; Xu H; Zhou Z; Ding X; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    J Med Chem; 2016 Sep; 59(17):7991-8007. PubMed ID: 27541578
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.
    Xu W; Zhao J; Sun J; Yin Q; Wang Y; Jiao Y; Liu J; Jiang S; Shao Y; Wang X; Ma L
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4882-8. PubMed ID: 26055365
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis, structure-activity relationships, and docking studies of N-phenylarylformamide derivatives (PAFAs) as non-nucleoside HIV reverse transcriptase inhibitors.
    Ma XD; He QQ; Zhang X; Yang SQ; Yang LM; Gu SX; Zheng YT; Chen FE; Dai HF
    Eur J Med Chem; 2012 Dec; 58():504-12. PubMed ID: 23164656
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structural Modifications of Diarylpyrimidine-quinolone Hybrids as Potent HIV-1 NNRTIs with an Improved Drug Resistance Profile.
    Mao TQ; He QQ; Chen WX; Tang GF; Chen FE; De Clercq E; Daelemans D; Pannecouque C
    Curr Pharm Des; 2016; 22(46):6982-6987. PubMed ID: 27875973
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.
    Ranise A; Spallarossa A; Cesarini S; Bondavalli F; Schenone S; Bruno O; Menozzi G; Fossa P; Mosti L; La Colla M; Sanna G; Murreddu M; Collu G; Busonera B; Marongiu ME; Pani A; La Colla P; Loddo R
    J Med Chem; 2005 Jun; 48(11):3858-73. PubMed ID: 15916438
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus.
    Liu N; Wei L; Huang L; Yu F; Zheng W; Qin B; Zhu DQ; Morris-Natschke SL; Jiang S; Chen CH; Lee KH; Xie L
    J Med Chem; 2016 Apr; 59(8):3689-704. PubMed ID: 27070547
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Non-nucleoside HIV-1 reverse-transcriptase inhibitors. Part 10. Synthesis and anti-HIV activity of 5-alkyl-6-(1-naphthylmethyl)pyrimidin-4(3H)-ones with a mono- or disubstituted 2-amino function as novel 'dihydro-alkoxy-benzyl-oxopyrimidine' (DABO) analogues.
    Wang Y; Chen FE; Balzarini J; De Clercq E; Pannecouque C
    Chem Biodivers; 2008 Jan; 5(1):168-76. PubMed ID: 18205120
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
    Cushman M; Casimiro-Garcia A; Hejchman E; Ruell JA; Huang M; Schaeffer CA; Williamson K; Rice WG; Buckheit RW
    J Med Chem; 1998 Jun; 41(12):2076-89. PubMed ID: 9622549
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Design, synthesis and biologic evaluation of diarylbenzimidazole derivatives as novel HIV-1 non-nucleoside reverse transcriptase inhibitors].
    Qin BJ; Zhou T; Lu H; Jiang SB; Xie L
    Yao Xue Xue Bao; 2009 Nov; 44(11):1233-43. PubMed ID: 21355324
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and anti-HIV activity of 4'-substituted 4'-thiothymidines: a new entry based on nucleophilic substitution of the 4'-acetoxy group.
    Haraguchi K; Shimada H; Tanaka H; Hamasaki T; Baba M; Gullen EA; Dutschman GE; Cheng YC
    J Med Chem; 2008 Mar; 51(6):1885-93. PubMed ID: 18311897
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
    Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and evaluation of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin-4-one analogues as anti-HIV-1 agents.
    Rawal RK; Tripathi R; Katti SB; Pannecouque C; De Clercq E
    Bioorg Med Chem; 2007 May; 15(9):3134-42. PubMed ID: 17349793
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
    Li X; Zhan P; Liu H; Li D; Wang L; Chen X; Liu H; Pannecouque C; Balzarini J; De Clercq E; Liu X
    Bioorg Med Chem; 2012 Sep; 20(18):5527-36. PubMed ID: 22883027
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
    Zhan P; Chen X; Li X; Li D; Tian Y; Chen W; Pannecouque C; De Clercq E; Liu X
    Eur J Med Chem; 2011 Oct; 46(10):5039-45. PubMed ID: 21872971
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.
    Liu Z; Tian Y; Liu J; Huang B; Kang D; De Clercq E; Daelemans D; Pannecouque C; Zhan P; Liu X
    Eur J Med Chem; 2017 Nov; 140():383-391. PubMed ID: 28987601
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
    Xu Z; Ba M; Zhou H; Cao Y; Tang C; Yang Y; He R; Liang Y; Zhang X; Li Z; Zhu L; Guo Y; Guo C
    Eur J Med Chem; 2014 Oct; 85():27-42. PubMed ID: 25072874
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Discovery and development of diarylpyrimidines (DAPYs) as next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
    Tian XT; Xie L
    Yao Xue Xue Bao; 2010 Feb; 45(2):177-83. PubMed ID: 21351427
    [TBL] [Abstract][Full Text] [Related]  

  • 60. C-2-aryl O-substituted HI-236 derivatives as non-nucleoside HIV-1 reverse-transcriptase inhibitors.
    Hunter R; Younis Y; Muhanji CI; Curtin TL; Naidoo KJ; Petersen M; Bailey CM; Basavapathruni A; Anderson KS
    Bioorg Med Chem; 2008 Dec; 16(24):10270-80. PubMed ID: 18996020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.